

pharmaceutical' composition comprising:  
a. [2R, 4S]-4-[(3,5-bis-trifluoromethyl-3,4-dihydro-2H-pyridin-2-ylidene)-phenyl]-N-phenyl-2-phenyl-2-oxo-1,2,3,4-tetrahydropyridine-3-carboxamide  
b. a compound of the Formula I


chain Formula IA

- 10

or, the open chain Formula IA


### Formula I

[illegible]




wherein R<sup>1</sup> is hydrogen or hydroxy or the pharmaceutically acceptable salts thereof; and

- 5                   c. a pharmaceutically acceptable carrier, vehicle or diluent.
2. A pharmaceutical composition as recited in claim 1 wherein R<sup>1</sup> is hydrogen or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition as recited in claim 2 comprising the hemicalcium salt of atorvastatin.
- 10               4. A pharmaceutical composition as recited in claim 1 wherein R<sup>1</sup> is 2-hydroxy or a pharmaceutically acceptable salt thereof.
5. A method for treating a mammal in need of therapeutic treatment comprising administering to said mammal a therapeutically effective amount of:
- 15                   a. a first compound, said first compound being [2R, 4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester; and
- b. a second compound, said second compound being a compound having the Formula I
- Sub  
A2



Formula I

or, the open chain Formula IA



Formula IA

wherein R<sup>1</sup> is hydrogen or hydroxy or the pharmaceutically acceptable salts thereof; and

wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable carrier, vehicle or diluent.

6. A method of treating a mammal as recited in claim 5 wherein R<sup>1</sup> is hydrogen or a pharmaceutically acceptable salt thereof.

7. A method of treating a mammal as recited in claim 6 comprising the hemicalcium salt of atorvastatin.

8. A method of treating a mammal as recited in claim 5 wherein R<sup>1</sup> is 2-hydroxy or a pharmaceutically acceptable salt thereof.

9. A method of treating a mammal as recited in claim 5 wherein atherosclerosis is prevented or treated.

10. A method of treating a mammal as recited in claim 5 wherein the progression of atherosclerotic plaques is slowed.

11. A method of treating a mammal as recited in claim 10 wherein the treatment of atherosclerosis causes the regression of atherosclerotic plaques.

12. A method of treating a mammal as recited in claim 5 wherein the therapeutic treatment comprises HDL elevation treatment and antihyperlipidemic treatment.


13. A method of treating a mammal as recited in claim 5 wherein angina is prevented.

14. A method of treating a mammal as recited in claim 5 wherein the therapeutic treatment comprises cardiac risk management.

15. A kit for achieving a therapeutic effect in a mammal comprising a therapeutically effective amount of a composition comprising:


a. [2R, 4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form;

b. a compound having the Formula I



Formula I

or, the open chain Formula IA



Formula IA

wherein  $R^1$  is hydrogen or hydroxy or the pharmaceutically acceptable salts thereof  
and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and

5 c. means for containing said first and second dosage forms.


16. A kit as recited in claim 15 wherein  $R^1$  is hydrogen or a pharmaceutically acceptable salt thereof.

17. A kit as recited in claim 16 comprising the hemicalcium salt of atorvastatin.

18. A kit as recited in claim 15 wherein  $R^1$  is 2-hydroxy or a pharmaceutically acceptable salt thereof.


19. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving a therapeutic effect in a mammal, which effect is greater than the individual therapeutic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical compositions comprises an amount of a Formula I or IA compound or a pharmaceutically acceptable salt thereof having the Formula I

15




Formula I

or, the open chain Formula IA




- 5            wherein R<sup>1</sup> is hydrogen or hydroxy and a pharmaceutically acceptable carrier, vehicle or diluent, said first pharmaceutical composition comprising of [2R, 4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester and a pharmaceutically acceptable carrier, vehicle or diluent.
- 10    20. A first pharmaceutical composition for use with a second pharmaceutical composition for achieving a therapeutic effect in a mammal, which effect is greater than the individual therapeutic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of [2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-
- 15    carboxylic acid ethyl ester and a pharmaceutically acceptable carrier, vehicle or diluent, said first pharmaceutical composition comprising an amount of a compound having the Formula I



Formula I

or, the open chain

Formula IA



Formula IA



Year	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	